The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Open accessAbstract
Background [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177 Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer.Methods In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous 177 Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling). Crossover from ARPI change to 177 Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. The primary endpoint was radiographic progression-free survival, defined as the time from randomisation until radiographic progression or death, assessed in the intention-to-treat population. Safety was a secondary endpoint. This study is registered with ClinicalTrials.gov (NCT04689828) and is ongoing. In this primary report of the study, we present primary (first data cutoff) and updated (third data cutoff) analyses of radiographic progression-free survival; all other data are based on the third data cutoff.Findings Overall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive 177 Lu-PSMA-617 (234 [50%] patients) or ARPI change (234 [50%]). Baseline characteristics were mostly similar between groups; median number of 177 Lu-PSMA-617 cycles was 6·0 (IQR 4·0-6·0). Of patients assigned to ARPI change, 134 (57%) crossed over to receive 177 Lu-PSMA-617. In the primary analysis (median time from randomisation to first data cutoff 7·26 months [IQR 3·38-10·55]), the median radiographic progression-free survival was 9·30 months (95% CI 6·77-not estimable) in the 177 Lu-PSMA-617 group versus 5·55 months (4·04-5·95) in the ARPI change group (hazard ratio [HR] 0·41 [95% CI 0·29-0·56]; p<0·0001). In the updated analysis at time of the third data cutoff (median time from randomisation to third data cutoff 24·11 months [IQR 20·24-27·40]), median radiographic progression-free survival was 11·60 months (95% CI 9·30-14·19) in the 177 Lu-PSMA-617 group versus 5·59 months (4·21-5·95) in the ARPI change group (HR 0·49 [95% CI 0·39-0·61]). The incidence of grade 3-5 adverse events was lower in the 177 Lu-PSMA-617 group (at least one event in 81 [36%] of 227 patients; four [2%] grade 5 [none treatment related]) than the ARPI change group (112 [48%] of 232; five [2%] grade 5 [one treatment related]).Interpretation 177 Lu-PSMA-617 prolonged radiographic progression-free survival relative to ARPI change, with a favourable safety profile. For patients with PSMA-positive metastatic castration-resistant prostate cancer who are being considered for a change of ARPI after progression on a previous ARPI, 177 Lu-PSMA-617 may be an effective treatment alternative.Funding Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The findings in the third data cutoff point thus far showed that those in the experimental group exhibited a statistically significant improvement in rPFS compared to the ARPI change group (median 11.6 months vs 5.59 months; HR:0.49).”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Preliminary safety analysis indicated that 177Lu-PSMA- 617 was generally well-tolerated with lower incidence of grade 3–5 adverse events as compared to control group, while OS data is still not fully mature”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Self-citationOlaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationScher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
(1997) · PubMed · Cited by 1,541
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Defining the clinically important difference in pain outcome measures
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000) · Pain · doi:10.1016/s0304-3959(00)00339-0 · Cited by 1,071
Research works printed but not linked: 1
- Raychaudhuri, 2024, Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: a retrospective multicenter cohort study, JCO Precis Oncol, 8
Cited by
Sorted by citations
Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Sandhu, S. K., Nguyen, A. D. K., Weickhardt, A. J., Lee, S.-T., Ng, S. S. W., Francis, R. J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00009-9 · Cited by 86
Garje, R., Riaz, I. B., Naqvi, S. A. A., Rumble, R. B., Taplin, M., Kungel, T. M., Herchenhorn, D., Zhang, T., Beckermann, K. E., Vapiwala, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00007 · Cited by 73
Buteau, J. P., Kostos, L. K., Jackson, P. A., Xie, J., Haskali, M. B., Alipour, R., McIntosh, L., Emmerson, B., MacFarlane, L., Martin, C. A., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00332-8 · Cited by 76
The molecular blueprint of targeted radionuclide therapy
Primac, I., Tabury, K., Tasdogan, A., Baatout, S., & Herrmann, K. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01069-z · Cited by 63
Self-citationFizazi, K. S., Chi, K. N., Shore, N. D., Herrmann, K., Bono, J. S. D., Castellano, D., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.07.003 · Cited by 59
Self-citationArmstrong, A. J., Morris, M. J., Abida, W. M., Aggarwal, R. R., Antonarakis, E. S., Attard, G., Beltran, H., Bryce, A. H., Carducci, M. A., Cheng, H. H., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02834 · Cited by 58
Self-citationKwan, E. M., Ng, S. W. S., Tolmeijer, S. H., Emmett, L., Sandhu, S. K., Buteau, J. P., Iravani, A., Joshua, A. M., Francis, R. J., Subhash, V. V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03704-9 · Cited by 49
The contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 50
Self-citationRecent advances in theranostics and oncology PET: emerging radionuclides and targets
Watabe, T., Hirata, K., Iima, M., Yanagawa, M., Saida, T., Sakata, A., Ide, S., Honda, M., Kurokawa, R., Nishioka, K., et al. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02090-z · Cited by 40
Kishan, A. U., Valle, L., Wilhalme, H., Felix, C., Nabong, R., Juarez-Casillas, J. E., Flores, K., Ma, T. M., Ludwig, V. B., Nakayama, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01553 · Cited by 42
Targeting the tumour cell surface in advanced prostate cancer
Boixareu, C., Taha, T., Venkadakrishnan, V. B., Bono, J. S. D., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01014-w · Cited by 43
Ninatti, G., Scilipoti, P., Pini, C., Barletta, F. M., Longoni, M., Gelardi, F., Sollini, M., Gandaglia, G., Sathekge, M. M., Montorsi, F., et al. (2025) · Theranostics · doi:10.7150/thno.106574 · Cited by 34
Fizazi, K. S., Attard, G., Azad, A. A., Baciarello, G., Beltran, H., Bjartell, A., Blanchard, P., Bossaert, F., Castro, E., Comperat, E., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.015 · Cited by 35
Self-citationAgarwal, N., Azad, A., Carles, J., Matsubara, N., Oudard, S. M., Fred Saad, C., Merseburger, A. S., Soares, A., McGregor, B. A., Żurawski, B. A., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00209-8 · Cited by 31
Radioligand Therapy in Cancer Management: A Global Perspective
Ninatti, G., Lee, S. T., & Scott, A. M. (2025) · Cancers · doi:10.3390/cancers17213412 · Cited by 32
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
Cimadamore, A., Boixareu, C., Sharp, A., Beltran, H., & Bono, J. S. D. (2025) · European Urology · doi:10.1016/j.eururo.2025.06.013 · Cited by 25
Fizazi, K. S., Morris, M. J., Shore, N. D., Chi, K. N., Crosby, M. J., Bono, J. S. D., Herrmann, K., Roubaud, G., Nagarajah, J., Fleming, M. T., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00189-5 · Cited by 29
Self-citationNovel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance
Wang, Z., Wang, J., Li, D., Wu, R., Huang, J., Ye, L., Tuo, Z., Yu, Q., Shao, F., Wusiman, D., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101232 · Cited by 20
Zhang, D., He, T., Shi, T., Huang, K., & Peng, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1553853 · Cited by 22
Aggarwal, R. R., Vuky, J., VanderWeele, D. J., Rettig, M. B., Heath, E. I., Quigley, D. A., Huang, J., Chumber, A. K., Cheung, A., Foye, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01989 · Cited by 19
Advances in Targeted Therapy for Metastatic Prostate Cancer
Grewal, K., Dorff, T. B., Mukhida, S. S., Agarwal, N., & Hahn, A. W. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01323-7 · Cited by 20
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01317-5 · Cited by 18
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer
Laudicella, R., Bauckneht, M., Burger, I. A., Cacciola, A., Fanti, S., Farolfi, A., Ficarra, V., Iagaru, A. H., Liberini, V., Pergolizzi, S., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07083-8 · Cited by 16
Liu, H., Guo, R., Zhang, X., Hu, J., Sun, S., Sun, S., Liu, J., Yang, Z., & Wang, R. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07617-0 · Cited by 16
Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose
Ferro‐Flores, G., Azorin‐Vega, E. P., Ocampo‐García, B., Luna‐Gutiérrez, M., Cruz-Nova, P., & Meléndez‐Alafort, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146968 · Cited by 15
Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions
Bent, E. H., & Morris, M. J. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01686-y · Cited by 16
Self-citationTagawa, S. T., Sartor, O., Piulats, J. M., Fred Saad, C., Fizazi, K. S., Reid, A., Beltran, H., Kramer, G., Mahammedi, H., Eiber, M., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01092-5 · Cited by 17
Self-citationLee, J.-H., & Kim, T. J. (2025) · Biomedicines · doi:10.3390/biomedicines13051132 · Cited by 14
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Bidkar, A. P., Peter, R., Wadhwa, A., Bobba, K. N., Bidlingmaier, S. M., Meher, N., Chou, J., Greenland, N., Dasari, C., Naik, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2850 · Cited by 12
Poon, D. M. C., Cheung, W. S. K., Chiu, P. K., Chung, D. H. S., Kung, J. B. T., Lam, D. C. M., Leung, A. K., Ng, A. C. F., O’Sullivan, J. M., Teoh, J. Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530580 · Cited by 11
Abida, W. M., Beltran, H., & Raychaudhuri, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473636 · Cited by 16
Wei, Z., Zhen, W., Chen, X. S., & Zhang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114543 · Cited by 11
Sandhu, S., Joshua, A. M., Emmett, L., Bressel, M., Anton, A., Spain, L., Horvath, L. G., Pasam, A., Tolmeijer, S. H., Akhurst, T., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00017-3 · Cited by 13
Advanced Imaging for Localized Prostate Cancer
Albers, P., & Kinnaird, A. S. (2024) · Cancers · doi:10.3390/cancers16203490 · Cited by 13
Konopnicki, A., Zaliznyak, M., Roy, M., & Jana, B. (2024) · Discover Oncology · doi:10.1007/s12672-024-01680-z · Cited by 12
The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond
Bernard‐Tessier, A., Naoun, N., Barraud, S., Flippot, R., Pobel, C., Rey, M., Baldini, C., Massard, C., Patrikidou, A., Fuerea, A. C., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251379416 · Cited by 10
Self-citationTaplin, M., Riaz, I. B., Rumble, R. B., Naqvi, S. A. A., Hope, T. A., Dias, M. S. F., He, H., Hotte, S. J., Emamekhoo, H., Murad, M. H., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02693 · Cited by 10
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Turco, F., Gillessen, S., Herrmann, K., Paone, G., & Omlin, A. G. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267730 · Cited by 11
Self-citationOmics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology
Fatima, Y., Jobre, K. N., Gómez‐Gómez, E., Małkiewicz, B., Vlahou, A., Mokou, M., Mischak, H., Frantzi, M., & Jankowski, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157475 · Cited by 11
Liu, K., Robinson, N., Tekoglu, E., Lozada, J., Yu, I. P. L., Tai, R. A., Özturan, D., Dikbas, U. M., Lack, N. A., Cox, M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c13307 · Cited by 10
Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy
Altunay, B., Schäfer, L., Morgenroth, A., Peña, Q., Lammers, T., Saar, M., Mottaghy, F. M., & Lütje, S. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270317 · Cited by 10
Yanagisawa, T., Matsukawa, A., Rajwa, P., Miszczyk, M., Fazekas, T., Pradère, B., Miyajima, K., Enei, Y., Cormio, A., Dematteis, A., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-025-01034-y · Cited by 11
Tendler, S., Gregorio, R. D., Balderes, P. J., Michel, A. L., Hoang, T., Bauer, D., Tully, K. M., Korsen, J. A., Lorenz, I. C., Khan, A. G., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505785123 · Cited by 9
Self-citationTargeting genomic instability in cancer
Yap, T. A., Manning, H. C., Sapra, P., Mills, G. B., & O’Connor, M. J. (2026) · Cell · doi:10.1016/j.cell.2026.03.035 · Cited by 12
Flauto, F., Neola, G., Caso, C., Signori, A., Fornarini, G., Scagliarini, S., Rossetti, S., Crocetto, F., Grillone, F., Costanzo, F. D., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.06.008 · Cited by 8
PSMA-Directed Theranostics in Prostate Cancer
Jajja, S. A., Sodhi, N., Parent, E. E., & Singh, P. (2025) · Biomedicines · doi:10.3390/biomedicines13081837 · Cited by 9
Belabaci, Z., Sleiay, M., Abdelshafi, A., Otmani, Z., Moubarak, E. S., & Amer, F. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102398 · Cited by 8
ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer
Woo, S., Russo, L., Withey, S. J., Dehghanpour, A., García‐Figueiras, R., Schoots, I. G., Petralia, G., Lakhani, A., Penzkofer, T., Pecoraro, M., et al. (2025) · European Radiology · doi:10.1007/s00330-025-12089-9 · Cited by 8
Saeed, F., Berchuck, J. E., Bilen, M. A., Gandhi, J. S., Nazha, B., Brown, J. T., Schuster, D. M., Jani, A. B., Yu, J., & Harik, L. R. (2025) · Cancer · doi:10.1002/cncr.70037 · Cited by 9
Civelek, A. C. (2026) · Cancers · doi:10.3390/cancers18020234 · Cited by 7
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Munzur, A. D., Herberts, C., Kwan, E. M., Emmett, L., Sandhu, S., Buteau, J. P., Iravani, A., Joshua, A. M., Francis, R. J., Lee, S.-T., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4001 · Cited by 10
PSMA PET as a Tool for Active Surveillance of Prostate Cancer—Where Are We at?
Carll, J., Bonaddio, J., & Lawrentschuk, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103580 · Cited by 7
Koh, N., Wei, M.-C., Lam, W., Tong, A., Kanesvaran, R., Wong, A., Chen, K., & Thang, S. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14174 · Cited by 5
Satapathy, S., Das, C. K., Goyal, S., Sood, A. K., Periasamy, K., Aggarwal, P., Preet, K., Singh, S., Mavuduru, R. S., Bora, G. S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269913 · Cited by 7
Kudura, K., Schaulin, Y., Templeton, A. J., Zellweger, T., Harms, W., Georis, R., Kreissl, M. C., & Foerster, R. (2025) · Cancers · doi:10.3390/cancers17132249 · Cited by 6
[177Lu]Lu-PSMA SPECT/CT for early response assessment using quantitative RECIP 1.0
Kassas, M., Devriendt, L., Manley, M., Guiot, T., Marin, C., Danieli, R., Taraji, L., Kristanto, P., Karfis, I., Woff, E., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07613-4 · Cited by 6
Belabaci, Z., Brignoli, G., Zilli, T., Grujić, M., Mohamad, I., Al‐Ibraheem, A., Shelan, M., & Afshar‐Oromieh, A. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07627-y · Cited by 6
Göğebakan, K. Ç., Kunst, N., Ghodsi, A., Owens, L., Iravani, A., & Etzioni, R. D. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271825 · Cited by 6
Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
Pepin, A. N., Kiess, A. P., Lukens, J. N., Mulugeta, P. G., & Taunk, N. K. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2024.10.014 · Cited by 7
Peng, C., Chen, C.-T., & Tang, I.-C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135970 · Cited by 7
Nagarajah, J., Kim, H., Nordquist, L. T., Prasad, V., Scott, N., Stevens, D. J., Fongenie, B., & Osborne, J. R. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07313-z · Cited by 5
Self-citationDuong, T. T., Sarno, D. D., Fakir, H., Bauman, G. S., Martinov, M., Thomson, R. M., & Lee, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1600821 · Cited by 5
Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer
Suh, M., & Joo Hyun, O. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00946-w · Cited by 5
Murthy, V., Kimura, K., Theus, L., Nguyen, A., Grogan, T., Lokre, O., Perk, T., Rettig, M. B., Drakaki, A., Shen, J., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270916 · Cited by 5
Nikitas, J. N., Holzgreve, A., Juarez, J. E., Kimura, K., Lira, S., Alam, H., Contreras, M., Theus, L., Nguyen, A. T., Ells, Z., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271231 · Cited by 5
Ghodsi, A., Owens, L., Demirci, R. A., Gafita, A., Cheng, H. H., Hawley, J. E., Raychaudhuri, R., Khan, H. M., Sunkara, R., Hsieh, A. C., et al. (2026) · Radiology · doi:10.1148/radiol.250649 · Cited by 5
Wenzel, M., Hoeh, B., Siech, C., Koll, F. J., Humke, C., Groener, D., Steuber, T. P., Graefen, M., Maurer, T., Banek, S., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07076-7 · Cited by 5
Kalender, E., Ekinci, E., Elboğa, U., & Şahin, E. (2025) · Biomedicines · doi:10.3390/biomedicines13030569 · Cited by 6
Ventura, D., Noto, B., Jauregui, N. R., Roll, W., & Rahbar, K. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001300 · Cited by 5
Enei, Y., Yanagisawa, T., Okada, A., Kuruma, H., Okazaki, C., Watanabe, K., Lenzo, N. P., Kimura, T., & Miki, K. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02086-9 · Cited by 5
Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer
Ashraf, B., McKenzie, J., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-025-01037-9 · Cited by 6
Baberwal, P., & Basu, S. K. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2589524 · Cited by 4
Current and future perspectives on radioligand therapy in advanced prostate cancer
Ahmed, B. S., & Ravi, P. K. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251409047 · Cited by 5
Obstacles and improvement strategies for CAR-T cell therapy in solid tumors
Luo, Z., Hu, Q., Ren, M., Wang, L., Zou, Q., Wen, X., Chen, S., Liu, Q., Luo, D., & Guo, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-04473-8 · Cited by 6
Clinical trials in cancer theranostics with potential near-term impact on clinical practice
Jadvar, H., Doroudinia, A., Conti, P. S., & Colletti, P. M. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf017 · Cited by 4
Fang, W., Chen, Y., Nie, M., Zhou, X., Liu, Y., Tao, H., Yang, B., & Wang, X. (2025) · Marine Drugs · doi:10.3390/md23050214 · Cited by 4
Kuo, P. H., Calais, J., & Crosby, M. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01151-7 · Cited by 4
Self-citationMirzaei, S., Schweighofer-Zwink, G., Ofner, H., Bektić, J., Fajković, H., von Guggenberg, E., Ponholzer, A., Kramer, G., Lusuardi, L., Gabriel, M., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02544-4 · Cited by 4
Liukaityte, R., Stenberg, V. Y., Kleinauskas, A., Juzenas, P., Urbanucci, A., & Juzeniene, A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02925-9 · Cited by 4
Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types
Oldan, J. D., Anugu, A., Islam, M. Z., Amindarolzarbi, A., Werner, R. A., Pomper, M. G., Sólnes, L. B., Almaguel, F. A., Moschos, S. J., Viglianti, B. L., et al. (2025) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2025.07.003 · Cited by 4
Prostate Cancer Treatments and Their Effects on Male Fertility: Mechanisms and Mitigation Strategies
Kaltsas, A., Razos, N., Kratiras, Z., Deligiannis, D., Stavropoulos, M., Adamos, K., Zachariou, A., Dimitriadis, F., Sofikitis, N., & Chrisofos, M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080360 · Cited by 4
Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors
Abel, M. L., Warner, A., Karzai, F. H., & Madan, R. A. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s549873 · Cited by 4
Suzuki, K., Miyake, H., Inaki, A., Takano, S., Kuboki, Y., Mizowaki, T., Nakamura, K., Ueno, M., Matsumoto, S., Obinata, D., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02858-3 · Cited by 4
Therapy strategies to defeat prostate cancer heterogeneity
Jadvar, H., & Iravani, A. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.11.025 · Cited by 4
Emmett, L., Swiha, M. M., Papa, N. P., Subramaniam, S., Crumbaker, M., Joshua, A. M., Nguyen, A., Weickhardt, A. J., Lee, S.-T., Ng, S., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01140-3 · Cited by 6
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
Mateo, J., & Zurita, A. J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01919-6 · Cited by 4
Wong, C. H. M., Nicoletti, R., Mazzone, E., & Eapen, R. S. (2024) · Current Opinion in Urology · doi:10.1097/mou.0000000000001234 · Cited by 4
Marshall, C. H., Antonarakis, E. S., & Patnaik, M. M. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101269 · Cited by 4
Stangl‐Kremser, J., Ricaurte‐Fajardo, A., Castellanos, S. H., Martinez‐Fundichely, A., Sun, M., Osborne, J. R., Nauseef, J. T., Tagawa, S. T., & Bander, N. H. (2025) · The Prostate · doi:10.1002/pros.24853 · Cited by 4
Czernin, J. G., Bodei, L., Modlin, I. M., & Calais, J. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269401 · Cited by 4
Oral Toxicities of PSMA-Targeted Therapies: Mitigation Strategies and Translational Opportunities
Emperumal, C. P., Kannan, N., Childs, D. S., & Keenan, B. P. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102452 · Cited by 3
Mehr, S., & Hauke, R. J. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00377-9 · Cited by 5
Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers
Ali, F. (2025) · Diagnostics · doi:10.3390/diagnostics15212737 · Cited by 3
Vogl, U. M., Merler, S., Angrisani, A., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K. S., James, N. D., Shore, N. D., Small, E. J., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116131 · Cited by 3
Self-citationMarini, I., Giunta, E. F., Nicolini, S., Grassi, I., Foca, F., Sarnelli, A., Iorio, V. D., Vizza, L., Giani, E., Celli, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07661-w · Cited by 4
Bölek, H., Araz, M., Soydal, Ç., Yekedüz, E., Küçük, Ö., & Ürün, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105088 · Cited by 3
Liu, Y., Wang, X., Pan, X., Huang, X., He, S., Zhang, J., Xu, X., & Song, S. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07704-2 · Cited by 3
Zhu, Y., Zhong, G., Zhang, W., Wei, W., Yin, B., & Zhang, K. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02700-x · Cited by 3
Amsberg, G. V., Bulkley, A., DeCongelio, M., Skiles, G., Grisolano, J., Yang, L., Masurkar, N., Morasso, C., Costanza-McDonald, S., Yin, X., et al. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102519 · Cited by 4
Metadata
- Authors
- Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., Roubaud, G., Študentová, H., Nagarajah, J., Mellado, B., Montesa-Pino, Á., Kpamegan, E., Ghebremariam, S., Kreisl, T. N., Wilke, C., Lehnhoff, K., Sartor, O., & Fizazi, K.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Research Institute Hospital 12 de Octubre (ES)
- National Center for Tumor Diseases (DE)
- Carolina Urologic Research Center (US)
- BC Cancer Agency (CA)
- Institut Català d'Oncologia (ES)
- Centre Léon Bérard (FR)
- Dana-Farber Cancer Institute (US)
- Centre Jean Perrin (FR)
- Institut Bergonié (FR)
- University Hospital Olomouc (CZ)
- Radboud University Medical Center (NL)
- Hospital Clínic de Barcelona (ES)
- Novartis (Switzerland) (CH)
- Mayo Clinic (US)
- Université Paris-Saclay (FR)
- Corresponding author
- Morris, Michael J
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 404
- Issue
- 10459
- Pages
- 1227-1239
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC12121614
- OpenAlex
- W4402552580
- Cited by
- 362
- References
- 47
- Citations by year
- 2026: 204 · 2025: 150 · 2024: 8
- FWCI
- 104.54
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-12-21)
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Novartis
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- 177Lu-PSMA-617, androgen receptor pathway inhibitors, abiraterone, enzalutamide, radiographic progression-free survival, radiographic progression, overall survival, radioligand therapy
- MeSH terms
- Progression-Free Survival, Aged, Androstenes, Benzamides, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Radioisotopes, Prostate-Specific Antigen, Taxoids, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
